What's Happening?
The Brookings Institution has released a detailed mapping of vertical integration within the U.S. health insurance sector, revealing that major insurers now control significant portions of the healthcare supply chain. This includes pharmacy benefit managers
(PBMs), physician practices, clinics, home health services, and ambulatory surgery centers. The study focuses on five major health insurance organizations: CVS-Aetna, Elevance, Humana, Kaiser Permanente, and UnitedHealth Group, which collectively insure approximately 126 million members and account for 69% of Medicare Advantage enrollment and 46% of commercial insurance enrollment. The analysis details the financial flows within these integrated entities, showing that substantial segments of spending involve related entities. For example, UnitedHealth Group reported $443.6 billion in 2025 operating revenues, with about 77% from health plans, while its Optum Health division generated $100.5 billion, of which 63.3% was paid by related entities. Similarly, CVS's health services, including Caremark PBM, generated $190.4 billion, with $25.8 billion (13.6%) from related entities.
Why It's Important?
This extensive vertical integration in the U.S. health insurance industry, as mapped by the Brookings Institution, carries significant implications for healthcare costs, competition, and patient care. Proponents argue that such integration can lead to greater data sharing, improved care coordination, and more efficient patient-treatment matching. However, critics fear increased opportunities for insurers to manipulate regulations, obscure profits through 'tunneling' (shifting funds between related entities), and limit market access for rivals. The study highlights how these structures can create financial flows that potentially circumvent regulations like Medical Loss Ratios (MLRs), which mandate how much premium revenue insurers must spend on healthcare services. This could lead to higher costs for consumers and reduced transparency in healthcare spending. The sheer scale of integration, with some organizations owning thousands of subsidiaries, suggests a complex web of financial relationships that could make it difficult for regulators to ensure fair practices and competitive markets.
What's Next?
The Brookings Institution's findings are likely to fuel ongoing debates among policymakers, regulators, and consumer advocates regarding the oversight of vertically integrated health insurance companies. The detailed financial mapping provides concrete data that could inform legislative efforts aimed at increasing transparency, preventing anti-competitive practices, and protecting consumers. Regulators, such as the Department of Justice and the Federal Trade Commission, may use this information to scrutinize mergers and acquisitions in the healthcare sector more closely and investigate potential antitrust violations. There could be calls for stricter enforcement of existing regulations and the development of new policies to address the unique challenges posed by these complex corporate structures. Stakeholders, including patient advocacy groups and independent healthcare providers, may leverage this research to advocate for reforms that promote competition and ensure that the benefits of integration, if any, are passed on to patients rather than solely to corporate bottom lines.
Beyond the Headlines
The Brookings Institution's report on vertical integration in health insurance points to a fundamental shift in the U.S. healthcare landscape, moving towards a model where insurers exert greater control over the entire patient journey. This trend raises profound questions about patient choice, the independence of medical professionals, and the potential for conflicts of interest. When insurers own providers and PBMs, there's a risk that treatment decisions could be influenced by financial incentives within the corporate structure rather than solely by patient needs. This could lead to steering patients towards in-network providers or specific medications that benefit the insurer's bottom line, potentially limiting access to preferred treatments or specialists. Furthermore, the concentration of power within a few large, integrated entities could stifle innovation from smaller, independent healthcare providers and technology companies, ultimately reducing dynamism and choice in the market. The ethical implications of such extensive control over healthcare services warrant careful consideration as the industry continues its consolidation.
